Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
FIG. 21 North America <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 22 North America <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
FIG. 23 Europe <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 24 Europe <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
FIG. 25 Asia-Pacific <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 26 Asia-Pacific <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 - <strong>2019</strong> (USD Million)<br />
FIG. 27 Rest Of The World (Row) <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2010 <strong>–</strong> 2014 (USD Million)<br />
FIG. 28 Rest Of The World (Row) <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong>, 2015 <strong>–</strong> <strong>2019</strong> (USD Million)<br />
FIG. 29 <strong>Market</strong> <strong>Share</strong> By Key Players: Br<strong>and</strong>ed Formulations For <strong>Erectile</strong> <strong>Dysfunction</strong> Treatment, 2012 (%)<br />
FIG. 30 Apricus Biosciences, Inc.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million)<br />
FIG. 31 Bayer AG: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million) (1 Euro = 1.35 USD)<br />
FIG. 32 Dong-A Pharmaceutical Co. Ltd.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million) (1 KRW = 0.0093 USD)<br />
FIG. 33 Eli Lilly & Co.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million)<br />
FIG. 34 Pfizer, Inc.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million)<br />
FIG. 35 S. K. Chemicals Co. Ltd.: Annual Revenue, 2010 <strong>–</strong> 2012 (USD Million) (1 KRW = 0.0093 USD)<br />
List of Tables<br />
TABLE 1 <strong>Market</strong> Snapshot: <strong>Global</strong> <strong>Erectile</strong> <strong>Dysfunction</strong> <strong>Drugs</strong> <strong>Market</strong><br />
TABLE 2 Causes Of <strong>Erectile</strong> <strong>Dysfunction</strong><br />
TABLE 3 Ongoing Clinical Trials In The U.S. For ED Treatment (Phase III)<br />
TABLE 4 Causes Of ED: Classes Of <strong>Drugs</strong> Used To Treat Chronic Diseases<br />
Transparency <strong>Market</strong> Research<br />
14
Change language